老年淋巴结阳性/高危淋巴结阴性早期乳腺癌接受伊班膦酸治疗时辅助卡培他滨对比无化疗的ICE随机临床试验
ICE为多中心3期随机试验,纳入≥65岁淋巴结阳性/高危淋巴结阴性早期乳腺癌患者,随机接受卡培他滨+伊班膦酸或伊班膦酸单药,激素受体阳性者推荐内分泌治疗。中位随访61.3个月,5年无侵袭性疾病生存率卡培他滨+伊班膦酸组78.8%对比伊班膦酸单药组75.0%(p=0.80),加用卡培他滨显著增加皮肤和胃肠道毒性。
要点
- ≥65岁淋巴结阳性/高危淋巴结阴性早期乳腺癌,卡培他滨+伊班膦酸对比伊班膦酸单药5年iDFS无显著差异(78.8% vs 75.0%,p=0.80)。
- 疗效不受年龄、淋巴结状态和激素受体状态影响。
- 加用卡培他滨导致皮肤和胃肠道毒性显著升高。
核心结论
- 在淋巴结阳性/高危淋巴结阴性老年早期乳腺癌患者中,辅助卡培他滨+伊班膦酸对比伊班膦酸单药未显示显著更好的无侵袭性疾病生存率,其中激素受体阳性患者同时接受了内分泌治疗。
研究设计与样本
- ICE为多中心3期临床试验,2020年更新了总生存长期随访,纳入≥65岁淋巴结阳性/高危淋巴结阴性早期乳腺癌患者。
- 患者随机接受卡培他滨2000 mg/m²第1-14天每3周一次共6周期+伊班膦酸(50 mg口服每日一次或替代6 mg静脉每4周一次)或伊班膦酸单药,疗程2年;激素受体阳性患者推荐内分泌治疗。
- 主要终点为无侵袭性疾病生存率,采用Cox比例风险回归和对数秩检验分析。
- 1409例随机患者中1358例(96.4%)开始治疗;卡培他滨+伊班膦酸组564例(83.4%)完成6周期卡培他滨;伊班膦酸完成情况:卡培他滨+伊班膦酸组513例(77.7%)对比伊班膦酸单药组516例(78.8%)。
- 中位年龄71岁(范围64-88),1099例(81%)激素受体阳性,705例(51.9%)淋巴结阴性。
主要发现
- 中位随访61.3个月时,5年无侵袭性疾病生存率卡培他滨+伊班膦酸组78.8%对比伊班膦酸单药组75.0%(p=0.80)。
- 疗效不受年龄、淋巴结状态和激素受体状态影响。
- 加用卡培他滨导致皮肤和胃肠道毒性显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: Evaluation of the impact of a de-escaleted chemotherapy regimen consisting of capecitabine (Cap) on invasive disease-free survival (iDFS) in patients ≥65 years with node-positive/high-risk node-negative early breast cancer (BC) receiving ibandronate (Ib). METHODS: ICE (Ib with or without Cap in Elderly patients with early breast cancer) was a multicentre phase 3 clinical trial with a 2020 update of long-term follow-up for overall survival enroling node-positive/high-risk node-negative patients ≥65 years with early BC. Patients were randomised to Cap 2000 mg/m² day 1-14 q3w for 6 cycles plus Ib (50 mg p.o. daily or alternatively 6 mg intravenous q4w) or Ib alone for 2 years. Endocrine therapy was recommended for hormone receptor (HR)-positive patients. The primary endpoint was iDFS analysed using Cox proportional hazards regression and log-rank analysis. RESULTS: 1358 (96.4%) of 1409 randomised patients started treatment. 564 (83.4%) completed 6 cycles of Cap. 513 (77.7%) and 516 (78.8%) completed Ib in the Cap+Ib and Ib alone arm, respectively. Median age was 71 (range 64-88) years, 1099 (81%) were HR-positive, 705 (51.9%) node-negative. At a median follow-up of 61.3 months, 5-year iDFS was 78.8% for Cap+Ib versus 75.0% for Ib alone (p = 0.80). Effects were independent of age, nodal, and HR status. The addition of Cap caused significantly higher skin and gastrointestinal toxicity. CONCLUSIONS: The adjuvant combination of Cap+Ib did not show significantly better iDFS than Ib alone in node-positive/high-risk node-negative older BC patients, of whom HR-positive patients were also treated with endocrine therapy. TRIAL REGISTRATION: Study in elderly patients with early breast cancer (ICE), NCT00196859, https://clinicaltrials.gov/ct2/show/NCT00196859?term=NCT00196859.
引用
- Schmidt M, Nitz U, Reimer T, et al. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer. 2023. PMID: 37797387. doi:10.1016/j.ejca.2023.113324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。